Hemostemix Inc. (CVE:HEM – Get Free Report) rose 34.5% on Thursday . The company traded as high as C$0.24 and last traded at C$0.20. Approximately 825,700 shares were traded during trading, an increase of 75% from the average daily volume of 472,417 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 34.5 %
The firm’s fifty day moving average price is C$0.09 and its 200-day moving average price is C$0.07. The company has a market cap of C$16.99 million, a price-to-earnings ratio of -9.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- The How and Why of Investing in Gold Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What is a support level?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- The 3 Best Fintech Stocks to Buy Now
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
